atherosclerotic cardiovascular disease

Twelve Must-Have Apps for Healthcare ExecutivesWe asked the Managed Healthcare Executive board to share their favorite app—for work or for play. Here’s what they said.
Patients who need PCSK9 inhibitors cant get themStudy: PCSK9 inhibitors are being rejected by insurers at very high rates even in high-risk patients like those with familial hypercholesterolemia.
Game-changing cholesterol-buster further reduces heart attack, strokeA new outcomes study shows that the PCSK9 inhibitor Repatha significantly reduced the risk of hard major adverse cardiovascular events in high-risk patients by 20%.